Back to top
more

AMAG Pharmaceuticals, Inc. (AMAG)

(Delayed Data from NSDQ)

$11.57 USD

11.57
544,003

+0.34 (3.03%)

Updated May 3, 2019 04:00 PM ET

After-Market: $11.57 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks News

AMAG Pharma's (AMAG) Q3 Earnings Beat, Lowers '17 Outlook

AMAG Pharmaceuticals' (AMAG) earnings surpassed estimates but missed revenues in the third quarter of 2017.

    AMAG Pharmaceuticals (AMAG) Down 6.6% Since Earnings Report: Can It Rebound?

    AMAG Pharmaceuticals (AMAG) reported earnings about a month ago. What's next for the company? We take a look at earnings estimates for some clues.

      AMAG's Filing for Feraheme's Label Expansion Accepted by FDA

      AMAG Pharmaceuticals (AMAG) announced that the FDA accepted its submission for the label expansion of Feraheme (ferumoxytol) and has set an action date of Feb 2, 2018.

        AMAG Pharma (AMAG) Incurs Narrower-than-Expected Loss in Q2

        AMAG Pharmaceuticals, Inc. (AMAG) posted narrower-than-expected loss and slightly beat revenue estimates in Q2.

          Spark Therapeutics (ONCE) Worth a Look: Stock Gains 5.7%

          Spark Therapeutics, Inc. (ONCE) shares rose above 5% in the last trading session.

            AMAG Pharmaceuticals Focuses on Product Development & Buyouts

            We issued an updated report on AMAG Pharmaceuticals, Inc. (AMAG) on Jul 4.

              Why Is AMAG Pharmaceuticals (AMAG) Down 15.6% Since the Last Earnings Report?

              AMAG Pharmaceuticals (AMAG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                Alpha & Omega Semiconductor, AMAG Pharmaceuticals and Trade Desk highlighted as Zacks Bull and Bear of the Day

                Alpha & Omega Semiconductor, AMAG Pharmaceuticals and Trade Desk highlighted as Zacks Bull and Bear of the Day

                  Brian Hamilton headshot

                  Bear of the Day: AMAG Pharmaceuticals (AMAG)

                  Licensing expenses, increased SG&A, and limited market share expansion are weighing this stock down.

                    What Makes AMAG Pharmaceuticals (AMAG) a Strong Sell?

                    AMAG Pharmaceuticals, Inc. (AMAG), which has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year.

                      AMAG Pharma (AMAG) Incurs Loss in Q1, Revenues Rise Y/Y

                      AMAG Pharmaceuticals, Inc. (AMAG) reported adjusted earnings of 99 cents per share in the first quarter of 2017 compared with earnings of 68 cents in the year-ago quarter

                        AMAG Files for FDA Approval of Subcutaneous Form of Makena

                        AMAG Pharmaceuticals, Inc. (AMAG) announced the submission of a supplemental New Drug Application (sNDA) to the FDA for the subcutaneous auto-injector form of its marketed drug Makena in the U.S.

                          TherapeuticsMD Falls on Likely Delay in TX-004HR Approval

                          Shares of TherapeuticsMD, Inc. (TXMD) have declined almost 25% since Monday when it received a letter from the FDA identifying deficiencies in the new drug application (NDA) for its dyspareunia drug, TX-400HR filed last July

                            5 Toxic Stocks to Get Rid Of or Play Short to Make Gains

                            Exaggerated price of toxic stocks can be attributed to either an irrational exuberance associated with them or some serious fundamental lacuna.

                              AMAG Pharma (AMAG) Incurs Loss in Q4, Revenues Lag Estimates

                              AMAG Pharmaceuticals, Inc. (AMAG) reported adjusted earnings of $1.36 per share in the fourth quarter of 2016, up from $1.04 in the year ago quarter.

                                Alexion (ALXN) Q4 Earnings: Can the Stock Pull a Surprise?

                                Alexion Pharmaceuticals, Inc. (ALXN) is scheduled to report fourth-quarter 2016 results on Feb 16, before the opening bell.

                                  Agios Pharmaceuticals (AGIO) Q4 Earnings: What's in Store?

                                  Agios Pharmaceuticals, Inc. (AGIO) is scheduled to report fourth-quarter and full-year 2016 results on Feb 16.

                                    Perrigo Company (PRGO) Q4 Earnings: Disappointment in Store?

                                    Perrigo Company plc (PRGO) is expected to report fourth-quarter 2016 results this month. Perrigo has a mixed track record as the company beat expectations in two of the last four quarters and missed the same in the other two.

                                      Teva (TEVA) Q4 Earnings: What's in Store for the Stock?

                                      Teva Pharmaceutical Industries Ltd. (TEVA) will be reporting fourth-quarter 2016 and full-year earnings on Feb 13, before the market opens.

                                        Gilead Sciences (GILD) Q4 Earnings: What's in the Cards?

                                        Gilead Sciences Inc. (GILD ) is scheduled to report fourth-quarter 2016 results on Feb 7, after the market closes.

                                          AMAG Down Despite Positive Data on Makena Auto-Injector

                                          AMAG Pharmaceuticals (AMAG) announced positive top-line results from its pharmacokinetic (PK) study on Makena, subcutaneous auto-injector.

                                            GW Pharmaceuticals (GWPH) Q1 Earnings: What's in Store?

                                            GW Pharmaceuticals plc (GWPH) is scheduled to report first-quarter fiscal 2017 results on Feb 7, before the opening bell.

                                              Is AMAG Pharmaceuticals (AMAG) A Good Value Pick?

                                              AMAG Pharmaceuticals (AMAG) is an inspired choice for value investors, as it is hard to beat its incredible lineup of statistics on this front.

                                                AMAG, Palatin Ink Deal to Focus on Female Sexual Disorder

                                                AMAG (AMAG) announced that it has entered into an agreement with Palatin (PTN) for the exclusive U.S. rights to develop and commercialize Rekynda.

                                                  New Strong Sell Stocks for January 9th

                                                  Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Monday